Revisiting Treatment Strategies: Addressing Epithelial-To Transition-Induced Resistance in Hepatocellular Carcinoma

dc.authorscopusid 57205555083
dc.authorscopusid 57865032900
dc.authorscopusid 55978761600
dc.authorscopusid 57202500098
dc.authorscopusid 35336983500
dc.authorscopusid 23483174100
dc.authorscopusid 23483174100
dc.authorwosid Iravani, Siavash/F-4046-2014
dc.authorwosid Vosough, Massoud/Aar-8970-2021
dc.authorwosid Zarrabi, Ali/U-2602-2019
dc.authorwosid Tahamtani, Yaser/B-9121-2018
dc.contributor.author Naserkhaki, Roghayeh
dc.contributor.author Shokouhian, Bahare
dc.contributor.author Tahamtani, Yaser
dc.contributor.author Khosravi, Arezoo
dc.contributor.author Iravani, Siavash
dc.contributor.author Zarrabi, Ali
dc.contributor.author Vosough, Massoud
dc.date.accessioned 2025-07-15T19:03:10Z
dc.date.available 2025-07-15T19:03:10Z
dc.date.issued 2025
dc.department Okan University en_US
dc.department-temp [Naserkhaki, Roghayeh; Vosough, Massoud] Univ Sci & Culture, Dept Dev Biol, Tehran 1665658822, Iran; [Naserkhaki, Roghayeh; Shokouhian, Bahare; Vosough, Massoud] ACECR, Royan Inst Stem Cell Biol & Technol, Cell Sci Res Ctr, Dept Regenerat Med, Tehran 1665659911, Iran; [Tahamtani, Yaser] ACECR, Royan Inst Stem Cell Biol & Technol, Cell Sci Res Ctr, Dept Stem Cells & Dev Biol, Tehran, Iran; [Tahamtani, Yaser] ACECR, Reprod Epidemiol Res Ctr, Dept Basic & Populat Based Studies NCD, Royan Inst, Tehran, Iran; [Khosravi, Arezoo] Istanbul Okan Univ, Fac Engn & Nat Sci, Dept Genet & Bioengn, TR-34959 Istanbul, Turkiye; [Zarrabi, Ali] Istinye Univ, Fac Engn & Nat Sci, Dept Biomed Engn, TR-34396 Istanbul, Turkiye; [Zarrabi, Ali] Yuan Ze Univ, Grad Sch Biotechnol & Bioengn, Taoyuan 320315, Taiwan; [Zarrabi, Ali] Saveetha Univ, Saveetha Inst Med & Tech Sci, Saveetha Dent Coll & Hosp, Dept Res Analyt, Chennai 600077, India; [Vosough, Massoud] Karolinska Inst, Inst Lab Med, Expt Canc Med, Huddinge, Sweden; [Vosough, Massoud] Karolinska Univ Hosp Huddinge, Huddinge, Sweden en_US
dc.description.abstract One of the major therapeutic challenges for hepatocellular carcinoma (HCC), the most form of primary liver cancer, is how to overcome drug resistance. Due to the high failure rate of systemic therapy in treating advanced HCC patients and the increasing recurrence rate, HCC is a highly lethal malignancy. Primary and acquired drug resistance are major contributing factors to the patients with advanced HCC who do not respond effectively to long-term systemic therapy. Therefore, it is essential to look into the molecular processes that lead to drug resistance. Different studies have indicated that epithelial-to-mesenchymal transition (EMT) plays a critical part in the emergence of drug resistance. Several signaling pathways regulate this phenomenon. This review primarily concentrates on drug resistance triggered by EMT, especially in the context of HCC. The key signaling pathways that cause drug resistance in HCC, including transforming growth factor-beta and epidermal growth factor receptor signaling, liver cancer stem cells, and noncoding RNAs, are highlighted in the present study, along with the most recent molecular targets discovered to prevent drug resistance. These targets could help develop novel and combinatory HCC therapy approaches. Therefore, this review aims to provide both the latest findings on molecular basis and potential solutions for HCC drug resistance. en_US
dc.description.woscitationindex Emerging Sources Citation Index
dc.identifier.doi 10.34133/bmef.0144
dc.identifier.issn 2765-8031
dc.identifier.pmid 40556662
dc.identifier.scopus 2-s2.0-105008948919
dc.identifier.scopusquality Q2
dc.identifier.uri https://doi.org/10.34133/bmef.0144
dc.identifier.uri https://hdl.handle.net/20.500.14517/8057
dc.identifier.volume 6 en_US
dc.identifier.wos WOS:001514068600001
dc.identifier.wosquality N/A
dc.language.iso en en_US
dc.publisher Amer Assoc Advancement Science en_US
dc.relation.publicationcategory Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı en_US
dc.rights info:eu-repo/semantics/closedAccess en_US
dc.title Revisiting Treatment Strategies: Addressing Epithelial-To Transition-Induced Resistance in Hepatocellular Carcinoma en_US
dc.type Article en_US

Files